Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00931255 · ClinicalTrials.gov registry record · Phase 4
Tacrolimus to Sirolimus Conversion for Delayed Graft Function
A Phase 4 study, sponsored by University of Maryland, Baltimore.
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT00931255 is a Phase 4 study that was terminated before completion, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants.
The verdict
NCT00931255, a Phase 4 study, was terminated before completion, sponsored by University of Maryland, Baltimore.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic allograft nephropathy. The investigators hypothesize that conversion from tacrolimus to sirolimus in renal transplant recipients with DGF/SGF in early months after surgery will improve graft function and decrease the progression of graft fibrosis.
Interventions
- DRUG Sirolimus
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2009-04 |
| Est. Completion | 2014-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00931255
The ClinicalTrials.gov registry entry for NCT00931255 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sirolimus is the first listed.
NCT00931255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00931255 about?
NCT00931255 is a clinical study titled "Tacrolimus to Sirolimus Conversion for Delayed Graft Function". The objective of this study is to evaluate the safety and efficacy of conversion from tacrolimus to sirolimus early after kidney transplantation in patients with delayed graft function (DGF)and slow graft function (SGF) in improving graft function and delaying chronic allograft nephropathy. The inve...
What is the current status of trial NCT00931255?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2009-04. Estimated completion is 2014-07.
What interventions are being tested in trial NCT00931255?
The interventions under investigation include: Sirolimus (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00931255?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.